Metabolic effects of troglitazone in NIDDM patients

Endocrinology and Metabolism, Supplement

Volumn 4, Issue 4, 1997, Pages 255-264

  Levin, Klaus ^a   Thye Roenn, Peter ^a   Foot, Elizabeth ^a   Beck Nielsen, Henning ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030729363     PISSN: 1074939X     EISSN: 20935978     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. DeFronzo RA, Ferrannini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hyper-tension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
3. Beck-Nielsen H, Groop L. Metabolic and genetic characterisation of prediabetic states, sequence of events leading to NIDDM. J. Clin. Invest. 1994; 94: 1714-1721.
4. Häring HU, Mehnert H. Pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle. Diabetologia 1993; 36: 176-182.
5. Martin BC, Warram JH, Krolewski RN, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of Type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340: 925-929.
6. Eriksson KF, Lindgarde F. Prevention of Type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia 1991; 34: 891-898.
7. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterisation of a new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
8. Hoffmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-1078.
9. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 1992; 41: 393-398.
10. Ibrahimi A, Teboul L, Gaillard D, Ez-zoubir A, Ailhaud G, Young P, Cawthorne MA, Grimaldi PA. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 1994; 46: 1070-1076.
11. Harris PKW, Kletzien RF. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol. Pharmacol. 1994; 45: 439-445.
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewert SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorγ (PPARγ). J. Biol. Chem. 1995; 270: 12953-12956.
13. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83: 803-812.
14. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650.
15. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycaemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
16. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P (for the troglitazone study group). Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-709.
17. Chaiken RL, Eckert-Norton M, Pasmantier R, Boden G, Ryan I, Gelfand RA, Lebovitz HE. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 1995; 38: 1307-1312.
18. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM. Improvement in glucose tolerance and insulin resistance in obese subjects treated with Troglitazone. N. Engl. J. Med. 1994; 331: 1188-1193.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Cauter EV, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels, comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
21. Ardawi MSM, Nasrat HAN, Bahnassy AA. Fructosamine in obese normal subjects and Type 2 diabetes. Diabetic Med. 1994; 11: 50-56.
22. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-630.
23. Hermann LS, Scherstén B, Bitzen PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of Metformin and Sulfonylurea, alone and in various combinations. Diabetes Care 1994; 17: 1100-1109.
24. UK Prospective Diabetes Study Group. Relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed NIDDM followed for three years. Br. Med. J. 1995; 310: 83-88.
25. Hermann LS, Karlsson JE, Sjöstrand Å. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur. J. Clin. Pharmacol. 1991; 41: 263-265.
26. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME, Xiang A, Azen S, Buchanan TA. Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes 1996; 45: 1572-1579.
27. Williams GD, Deldar A, Jordan WH, Gries C, Long GG, Dimarchi RD. Subchronic toxicity of the thiazolidinedione, Tanabe-174 (LY282449), in the rat and dog. (Abstract), Diabetes 1993; 42 (Suppl. 1): 186.
28. Espinal J, Ravel D, Challel S, Nanteuil G, Duhault J. Thiazolidinediones (TZD): euglycaemic and haematological side effects of novel TZD. (Abstract), Diabetologia 1995; 38 (Suppl. 1): 771.
29. Gimble GM, Robinson CE, Xiying W, Kelly KA, Rodriquez BR, Kliewer SA, Lehmann JM, Morris DC. Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. 1996; 50: 1087-1094.
30. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-794.
31. Rebrin K, Steil GM, Getty L, Bergman R. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995; 44: 1038-1045.
32. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38: 1213-1217.